Cargando…
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a limited efficacy in the treatment of metastatic disease. Metastatic cells have specific features that render them less sensitive to therapy...
Autores principales: | PosthumaDeBoer, J., Witlox, M. A., Kaspers, G. J. L., van Royen, B. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081058/ https://www.ncbi.nlm.nih.gov/pubmed/21461590 http://dx.doi.org/10.1007/s10585-011-9384-x |
Ejemplares similares
-
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2011) -
Small cell osteosarcoma of a toe phalanx: a case report and review of literature
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2010) -
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
por: PosthumaDeBoer, J, et al.
Publicado: (2013) -
Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin
por: De Boer, Jantine Posthuma, et al.
Publicado: (2012) -
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)